158 related articles for article (PubMed ID: 33284003)
1. Selection of a d-Enantiomeric Peptide Specifically Binding to PHF6 for Inhibiting Tau Aggregation in Transgenic Mice.
Zhang X; Zhang X; Zhong M; Zhao P; Guo C; Li Y; Wang T; Gao H
ACS Chem Neurosci; 2020 Dec; 11(24):4240-4253. PubMed ID: 33284003
[TBL] [Abstract][Full Text] [Related]
2. Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display.
Malhis M; Kaniyappan S; Aillaud I; Chandupatla RR; Ramirez LM; Zweckstetter M; Horn AHC; Mandelkow E; Sticht H; Funke SA
Chembiochem; 2021 Nov; 22(21):3049-3059. PubMed ID: 34375027
[TBL] [Abstract][Full Text] [Related]
3. Mirror-Image Phage Display for the Selection of D-Amino Acid Peptide Ligands as Potential Therapeutics.
Malhis M; Funke SA
Curr Protoc; 2024 Feb; 4(2):e957. PubMed ID: 38372457
[TBL] [Abstract][Full Text] [Related]
4. On the Tracks of the Aggregation Mechanism of the PHF6 Peptide from Tau Protein: Molecular Dynamics, Energy, and Interaction Network Investigations.
Fagnen C; Giovannini J; Catto M; Voisin-Chiret AS; Sopkova-de Oliveira Santos J
ACS Chem Neurosci; 2022 Oct; 13(19):2874-2887. PubMed ID: 36153969
[TBL] [Abstract][Full Text] [Related]
5. Integrating in vitro and in silico approaches to evaluate the "dual functionality" of palmatine chloride in inhibiting and disassembling Tau-derived VQIVYK peptide fibrils.
Haj E; Losev Y; Guru KrishnaKumar V; Pichinuk E; Engel H; Raveh A; Gazit E; Segal D
Biochim Biophys Acta Gen Subj; 2018 Jul; 1862(7):1565-1575. PubMed ID: 29634991
[TBL] [Abstract][Full Text] [Related]
6. Disclosing the Mechanism of Spontaneous Aggregation and Template-Induced Misfolding of the Key Hexapeptide (PHF6) of Tau Protein Based on Molecular Dynamics Simulation.
Liu H; Zhong H; Liu X; Zhou S; Tan S; Liu H; Yao X
ACS Chem Neurosci; 2019 Dec; 10(12):4810-4823. PubMed ID: 31661961
[TBL] [Abstract][Full Text] [Related]
7. Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.
Dammers C; Yolcu D; Kukuk L; Willbold D; Pickhardt M; Mandelkow E; Horn AH; Sticht H; Malhis MN; Will N; Schuster J; Funke SA
PLoS One; 2016; 11(12):e0167432. PubMed ID: 28006031
[TBL] [Abstract][Full Text] [Related]
8. Purpurin modulates Tau-derived VQIVYK fibrillization and ameliorates Alzheimer's disease-like symptoms in animal model.
Viswanathan GK; Shwartz D; Losev Y; Arad E; Shemesh C; Pichinuk E; Engel H; Raveh A; Jelinek R; Cooper I; Gosselet F; Gazit E; Segal D
Cell Mol Life Sci; 2020 Jul; 77(14):2795-2813. PubMed ID: 31562564
[TBL] [Abstract][Full Text] [Related]
9. Identification of Aggregation Mechanism of Acetylated PHF6* and PHF6 Tau Peptides Based on Molecular Dynamics Simulations and Markov State Modeling.
Shah SJA; Zhang Q; Guo J; Liu H; Liu H; Villà-Freixa J
ACS Chem Neurosci; 2023 Nov; 14(21):3959-3971. PubMed ID: 37830541
[TBL] [Abstract][Full Text] [Related]
10. Membrane-mediated fibrillation and toxicity of the tau hexapeptide PHF6.
Fanni AM; Vander Zanden CM; Majewska PV; Majewski J; Chi EY
J Biol Chem; 2019 Oct; 294(42):15304-15317. PubMed ID: 31439664
[TBL] [Abstract][Full Text] [Related]
11. Atomistic Insights into the Inhibitory Mechanism of Tyrosine Phosphorylation against the Aggregation of Human Tau Fragment PHF6.
Zou Y; Guan L; Tan J; Qi B; Wang Y; Zhang Q; Sun Y
J Phys Chem B; 2023 Jan; 127(1):335-345. PubMed ID: 36594671
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the Inhibitory Mechanism of Naphthoquinone-Dopamine on the Aggregation of Tau Core Fragments PHF6* and PHF6.
Zou Y; Qi B; Tan J; Guan L; Zhang Q; Sun Y; Huang F
ACS Chem Neurosci; 2023 Sep; 14(17):3265-3277. PubMed ID: 37585669
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tau amyloid formation and disruption of its preformed fibrils by Naphthoquinone-Dopamine hybrid.
Paul A; Viswanathan GK; Huber A; Arad E; Engel H; Jelinek R; Gazit E; Segal D
FEBS J; 2021 Jul; 288(14):4267-4290. PubMed ID: 33523571
[TBL] [Abstract][Full Text] [Related]
14. A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro.
Aillaud I; Kaniyappan S; Chandupatla RR; Ramirez LM; Alkhashrom S; Eichler J; Horn AHC; Zweckstetter M; Mandelkow E; Sticht H; Funke SA
Alzheimers Res Ther; 2022 Jan; 14(1):15. PubMed ID: 35063014
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the Role of ATP on PHF6 Aggregation.
Pal S; Roy R; Paul S
J Phys Chem B; 2022 Jul; 126(26):4761-4775. PubMed ID: 35759245
[TBL] [Abstract][Full Text] [Related]
16. Terminal Capping of an Amyloidogenic Tau Fragment Modulates Its Fibrillation Propensity.
Arya S; Ganguly P; Arsiccio A; Claud SL; Trapp B; Schonfeld GE; Liu X; Lazar Cantrell K; Shea JE; Bowers MT
J Phys Chem B; 2020 Oct; 124(40):8772-8783. PubMed ID: 32816481
[TBL] [Abstract][Full Text] [Related]
17. Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.
Aillaud I; Funke SA
Cell Mol Neurobiol; 2023 Apr; 43(3):951-961. PubMed ID: 35596819
[TBL] [Abstract][Full Text] [Related]
18. Mapping the configurational landscape and aggregation phase behavior of the tau protein fragment PHF6.
Pretti E; Shell MS
Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2309995120. PubMed ID: 37983502
[TBL] [Abstract][Full Text] [Related]
19. Positional effects of phosphorylation on the stability and morphology of tau-related amyloid fibrils.
Inoue M; Konno T; Tainaka K; Nakata E; Yoshida HO; Morii T
Biochemistry; 2012 Feb; 51(7):1396-406. PubMed ID: 22304362
[TBL] [Abstract][Full Text] [Related]
20. Effects of All-Atom Molecular Mechanics Force Fields on Amyloid Peptide Assembly: The Case of PHF6 Peptide of Tau Protein.
Man VH; He X; Gao J; Wang J
J Chem Theory Comput; 2021 Oct; 17(10):6458-6471. PubMed ID: 34491058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
